Showing 71-80 of 308 results for "".
- IV Glutathione for Skin Whitening is Risky Business, UK Doctor Warnshttps://practicaldermatology.com/news/iv-glutathione-for-skin-whitening-is-risky-business-uk-doctor-warns/2458444/Skin bleaching with IV glutathione is on the rise, despite potential risks, warns a doctor in The BMJ. Both the US Food and Drug Administration (FDA) and the Dermatology Society in the Philippines -- where the practice i
- Adriane M. Brown Joins Allergan's Board of Directorshttps://practicaldermatology.com/news/adriane-m-brown-joins-allergans-board-of-directors/2458375/Adriane M. Brown is joining Allergan’s board of directors effective February 2017. Ms. Brown is currently President and Chief Operating Officer of Intellectual Ventures LLC, a private global invention company focused on providing access to valua
- FDA Approves Novartis Cosentyx as First IV Formulation IL-17A Antagonist for PsAhttps://practicaldermatology.com/news/fda-approves-novartis-cosentyx-as-first-iv-formulation-il-17a-antagonist-for-psa/2462048/The US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Novartis’ Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx
- TOOsonix A/S Rolls Out System ONE-M for Aesthetic Treatmentshttps://practicaldermatology.com/news/toosonix-as-rolls-out-system-one-m-for-aesthetic-treatments/2460449/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultrasound device operati
- Dr. Richard M. Goldfarb Named Medical Director of DBM Corporationhttps://practicaldermatology.com/news/dr-richard-m-goldfarb-named-medical-director-ofdbm-corporation/2460145/Richard M. Goldfarb MD, is the new Medical Director of DBM Corporation Inc. is the official US representative of MIRACU PDO Threads. In this role, Dr. Goldfarb, the founder of the Center for SmartLipo & Plastic Surgery in the Philadelphia
- Lisa M. Donofrio, MD Takes Reins of ASDS/ASDSAhttps://practicaldermatology.com/news/lisa-m-donofrio-md-takes-reins-of-asdsasdsa/2458023/Lisa M. Donofrio, MD, is the new President of the American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA). Along with her fellow officers and the ASDS / ASDSA
- Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directorshttps://practicaldermatology.com/news/third-harmonic-bio-appoints-thomas-m-soloway-to-its-board-of-directors/2461292/Thomas M. Soloway is now a member of Third Harmonic Bio, Inc.’s Board of Directors. Mr. Soloway brings more than 25 years of experience in the life sciences industry, with senior roles in strategy, operations, corporate finance and venture capital to the company,
- Message from ASLMS President Dr. Paul M. Friedmanhttps://practicaldermatology.com/news/message-from-aslms-president-dr-paul-m-friedman/2461221/Dr. Paul M. Friedman, president of the American Society for Laser Medicine and Surgery (ASLMS), is calling on members to expand philanthropic programs that can help change lives with lasers. “In the coming year, I will be looking to the membership to bring their talents forwa
- TOOsonix System ONE-M BCC Clinical Trial Updatehttps://practicaldermatology.com/news/toosonix-system-one-m-bcc-clinical-trial-update/2461162/The first basal cell carcinoma (BCC) patients have been treated with TOOsonix A/S’s System ONE-M device. The TOOsonix high-intensity focused ultrasound (HIFU) delivers highly accurate doses of energy to focal points in a chosen depth. It operates at 20 MHz to
- Dermavant Sciences Appoints Dr. Philip M. Brown as Chief Medical Officerhttps://practicaldermatology.com/news/dermavant-sciences-appoints-dr-philip-m-brown-as-chief-medical-officer/2459949/Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at G